Equities analysts expect Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) to announce $ 6.20 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Thermo Fisher Scientific’s earnings, with the highest EPS estimate coming in at $ 6.55 and the lowest estimate coming in at $ 5.62. Thermo Fisher Scientific posted earnings of $ 7.21 per share during the same quarter last year, which indicates a negative year over year growth rate of 14%. The business is expected to announce its next earnings report before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year earnings of $ 22.52 per share for the current year, with EPS estimates ranging from $ 22.43 to $ 22.72. For the next year, analysts anticipate that the business will report earnings of $ 24.06 per share, with EPS estimates ranging from $ 23.36 to $ 24.90. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE: TMO – Get Rating) last released its quarterly earnings results on Wednesday, February 2nd. The medical research company reported $ 6.54 EPS for the quarter, beating analysts’ consensus estimates of $ 5.22 by $ 1.32. The business had revenue of $ 10.70 billion during the quarter, compared to analyst estimates of $ 9.25 billion. Thermo Fisher Scientific had a return on equity of 26.34% and a net margin of 19.70%. Thermo Fisher Scientific’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $ 7.09 EPS.
TMO has been the subject of a number of analyst reports. Barclays assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, January 26th. They issued an “overweight” rating and a $ 700.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $ 718.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, February 3rd. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $ 700.00 to $ 605.00 and set an “equal weight” rating for the company in a research report on Thursday, February 3rd. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $ 609.00 target price for the company. in a research report on Monday, January 24th. Finally, StockNews.com started coverage on Thermo Fisher Scientific in a research report on Thursday, March 31st. They set a “hold” rating for the company. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $ 645.31.
NYSE TMO traded down $ 23.19 on Monday, reaching $ 585.67. The company had a trading volume of 1,470,110 shares, compared to its average volume of 1,640,421. The stock has a market capitalization of $ 229.11 billion, a P / E ratio of 30.11, a P / E / G ratio of 1.93 and a beta of 0.82. The company’s fifty day moving average is $ 567.36 and its 200 day moving average is $ 599.03. Thermo Fisher Scientific has a 52-week low of $ 438.72 and a 52-week high of $ 672.34. The company has a quick ratio of 1.12, a current ratio of 1.50 and a debt-to-equity ratio of 0.79.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 14th. Stockholders of record on Wednesday, March 16th will be given a dividend of $ 0.30 per share. This represents a $ 1.20 dividend on an annualized basis and a dividend yield of 0.20%. The ex-dividend date is Tuesday, March 15th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $ 0.26. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.17%.
In other news, Director Jim P. Manzi sold 1,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 14th. The stock was sold at an average price of $ 563.95, for a total transaction of $ 845,925.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.44% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Carnegie Capital Asset Management LLC raised its holdings in shares of Thermo Fisher Scientific by 5.4% during the 1st quarter. Carnegie Capital Asset Management LLC now owns 40,705 shares of the medical research company’s stock valued at $ 24,043,000 after buying an additional 2,071 shares in the last quarter. Dynamic Advisor Solutions LLC raised its holdings in shares of Thermo Fisher Scientific by 35.8% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 4,649 shares of the medical research company’s stock valued at $ 2,746,000 after buying an additional 1,226 shares in the last quarter. Veriti Management LLC raised its holdings in shares of Thermo Fisher Scientific by 9.2% during the 1st quarter. Veriti Management LLC now owns 2,110 shares of the medical research company’s stock valued at $ 1,246,000 after buying an additional 178 shares in the last quarter. Sarasin & Partners LLP purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $ 79,878,000. Finally, Maryland State Retirement & Pension System increased its stake in Thermo Fisher Scientific by 0.8% in the 1st quarter. Maryland State Retirement & Pension System now owns 30,416 shares of the medical research company’s stock worth $ 17,965,000 after purchasing an additional 237 shares during the period. 86.17% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Company Profile (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.